RELATIONSHIP BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA

被引：0
|
作者：
Beauchemin, C. [1 ]
Johnston, J. B. [2 ]
Lapierre, M. [1 ]
Aissa, F. [3 ]
Lachaine, J. [1 ]
机构：
[1] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
[2] Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada
[3] Lundbeck Canada Inc, Market Access & Hlth Outcome Dept, Montreal, PQ, Canada
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：350 / 350
页数：1
相关论文
共 50 条
  • [21] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [22] Concordance index: Surrogacy of progression-free survival for overall survival
    Fan, Yiwei
    Yin, Guosheng
    [J]. CONTEMPORARY CLINICAL TRIALS, 2021, 104
  • [23] Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology
    Hess, Lisa M.
    Brnabic, Alan
    Mason, Oksana
    Lee, Pablo
    Barker, Scott
    [J]. JOURNAL OF CANCER, 2019, 10 (16): : 3717 - 3727
  • [24] Association between hypertension and overall survival in chronic lymphocytic leukemia
    Vainer, Noomi
    Brieghel, Christian
    Hjalgrim, Henrik
    Niemann, Carsten
    Rotbain, Emelie Hamotal Curovic
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 : S22 - S23
  • [25] THE ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN ONCOLOGY TRIALS: A SIMULATION EXERCISE
    Wu, D. B. C.
    Manjula, I. S.
    Yu, D.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S198 - S198
  • [26] Response, Progression-Free Survival, and Overall Survival of patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities
    Woyach, Jennifer A.
    Ruppert, Amy S.
    Blum, Kristie A.
    Jones, Jeffrey Alan
    Flynn, Joseph M.
    Johnson, Amy J.
    Grever, Michael R.
    Byrd, John C.
    Heerema, Nyla A.
    [J]. BLOOD, 2010, 116 (21) : 1019 - 1020
  • [27] Irreconcilable Differences: The Divorce Between Response Rates, Progression-Free Survival, and Overall Survival
    Merino, Margret
    Kasamon, Yvette
    Theoret, Marc
    Pazdur, Richard
    Kluetz, Paul
    Gormley, Nicole
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2706 - +
  • [28] Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study
    Lozanski, Gerard
    Ruppert, Amy S.
    Heerema, Nyla A.
    Lozanski, Arletta
    Lucas, David M.
    Gordon, Amber
    Gribben, John G.
    Morrison, Vicki A.
    Rai, Kanti M.
    Marcucci, Guido
    Larson, Richard A.
    Byrd, John C.
    [J]. LEUKEMIA & LYMPHOMA, 2012, 53 (09) : 1743 - 1748
  • [29] The addition of rituximab to fludarabine significantly improves progression-free and overall survival in previously untreated chronic lymphocytic leukemia (CLL) patients.
    Byrd, JC
    Rai, KR
    Peterson, BL
    Appelbaum, FR
    Morrison, VA
    Kolitz, JE
    Shepherd, L
    Hines, JD
    Schiffer, CA
    Larson, RA
    [J]. BLOOD, 2003, 102 (11) : 73A - 73A
  • [30] Minimal Residual Disease Status with Venetoclax Monotherapy Is Associated with Progression-Free Survival in Chronic Lymphocytic Leukemia
    Wierda, William G.
    Roberts, Andrew W.
    Ghia, Paolo
    Brown, Jennifer R.
    Stilgenbauer, Stephan
    Cymbalista, Florence
    Lamanna, Nicole
    Seymour, John F.
    Boettcher, Sebastian
    Breuleux, Madlaina
    Chyla, Brenda
    Zhou, Lang
    Nielsen, Jacqueline
    Kim, Su Young
    Potluri, Jalaja
    Maher, Johnathan C.
    Hillmen, Peter
    [J]. BLOOD, 2018, 132
12345